SEC Form 8-K filed by Werewolf Therapeutics Inc.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
(Exact name of registrant as specified in its charter)
| (State or Other Jurisdiction of Incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
| (Address of Principal Executive Offices) | (Zip Code) |
Registrant’s telephone number, including area code:
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class |
Trading |
Name of each exchange on which registered | ||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Item 5.07. Submission of Matters to a Vote of Security Holders.
At the annual meeting of stockholders of the Company held on May 24, 2024, the Company’s stockholders voted on the following proposals:
(a) The stockholders of the Company elected Michael Atkins, M.D., Luke Evnin, Ph.D., and Alon Lazarus, Ph.D. as Class III directors, each for a three-year term ending at the annual meeting of stockholders to be held in 2027. The results of the stockholders’ vote with respect to the election of the Class III directors were as follows:
| Name |
Votes For |
Votes Withheld |
Broker Non-Votes | |||
| Michael Atkins, M.D. |
31,566,857 | 19,721 | 5,145,182 | |||
| Luke Evnin, Ph.D. |
20,732,054 | 10,854,524 | 5,145,182 | |||
| Alon Lazarus, Ph.D. |
31,503,628 | 82,950 | 5,145,182 |
(b) The stockholders of the Company ratified the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2024. The results of the stockholders’ vote with respect to such ratification were as follows:
| For |
Against |
Abstain | ||
| 36,686,933 | 41,889 | 2,938 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| WEREWOLF THERAPEUTICS, INC. | ||||||
| Date: May 28, 2024 | By: | /s/ Jonathan Owen | ||||
| Jonathan Owen | ||||||
| Secretary | ||||||